Hepatitis B virus and HIV coinfection in low-income countries: Unmet needs

Clinical Infectious Diseases

Volumn 46, Issue 3, 2008, Pages 367-369

  Puoti, Massimo ^a,b   Manno, Daniela ^a   Nasta, Paola ^a   Carosi, Giampiero ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Divisione di Malattie Infettive   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; TENOFOVIR;

ENDEMIC DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOWEST INCOME GROUP; NOTE; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS TRANSMISSION;

DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; POVERTY;

EID: 39349094194     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/525532     Document Type: Note

References (18)

1. Lai CL, Ratziu V, Yeun MF, Poynard T. Viral hepatitis B. Lancet 2003; 362:2089-94.
2. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349:1269-76.
3. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34:1329-39.
4. Joint United Nations Programme on HIV/ AIDS (UNAIDS) and World Health Organization (WHO) AIDS epidemic update: December 2006. Available at: http://www.unaids.org/en/HIV_data/2007EpiUpdate/default.asp. Accessed 13 December 2007.
5. Konopnicki D, Mocroft A, de Wit S. Hepatitis B and HIV: prevalence, AIDS progression, response to HAART and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:2117-25.
6. Merican I, Guan R, Amarapuka D, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000; 15:1356-61.
7. Vardas E, Mathai M, Blaauw D, McAnerney J, Coppin A, Sim J. Preimmunization epidemiology of hepatitis B virus infection in South African children. J Med Virol 1999; 58:111-5.
8. Roingeard P, Diouf A, Sankale JL, et al. Perinatal transmission of hepatitis B virus in Senegal, West Africa. Viral Immunol 1993; 6:65-73.
9. Beasley RP, Trepo C, Stevens C, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977; 105:94-8.
10. Rouet F, Chaix M-L, Inwoley A, et al. Frequent occurrence of chronic hepatitis B virus (HBV) infections among West African human immunodeficiency virus type 1-infected children. Clin Inf Dis 2008; 46:361-6.
11. Weber R, Sabin C, Friis-Moller N, et al. Liver-related deaths in persons infected with the HIV: the D:A:D study. Arch Intern Med 2006; 166:1632-41.
12. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006; 44(1 Suppl):S65-70.
13. Puoti M, Cozzi-Lepri A, Arici C, et al. Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg-and HIV-positive individuals: results from an inter-cohort analysis. Antivir Ther 2006; 11:567-74.
14. Thio C, Seaberg E, Skolasky R. HIV-1, hepatitis B virus, and risk of liver-relatedmortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002; 360:1921-6.
15. Matthews G, Bartholomeusz A, Locarnini S. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20:863-70.
16. Thio C, Sulkowski M, Thomas D. Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box. Clin Infect Dis 2005; 41:1035-40.
17. Alberti A, Clumeck N, Collins S. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42:615-24 (erratum: J Hepatol 2005; 43: 1098).
18. Hoffmann C, Thio C. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007; 7:402-9.